Organon EBIT

Organon (OGN) currently reports a EBIT of $870M as of June 2026. That compares with $880M in the prior-year period — down 0.9% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Organon's EBIT history and peer comparisons.

Organon's EBIT decreased from $880M to $870M — a 0.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Organon's EBIT of $870M is lower than the Healthcare sector average of $22B. That is roughly 96.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Organon reported $870M in EBIT as of June 2026. That compares with $880M in the prior-year period — down 0.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $870M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Organon, and consider following OGN for alerts when major investors trade the stock.